- Visilizumab
-
Visilizumab ? Monoclonal antibody Type Whole antibody Source Humanized (from mouse) Target CD3 receptor Clinical data Pregnancy cat. ? Legal status ? Identifiers ATC code None Chemical data Formula ? 
(what is this?) (verify)Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.[1]
PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] as of July 2009[update].
Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.[6]
References
- ^ "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Archived from the original on 2007-09-15. http://web.archive.org/web/20070915083341/http://www.pdl.com/index.cfm?navId=43. Retrieved 2008-02-11.
- ^ "PDL Lands in a Hazard". http://www.fool.com/investing/high-growth/2007/08/29/pdl-lands-in-the-hazard.aspx. Retrieved 2009-05-27.
- ^ "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma". ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00938626. Retrieved 2010-03-15.
- ^ Kaufman, A; Herold, KC (2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/metabolism research and reviews 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985.
- ^ "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes". ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00378508.
- ^ Malviya, G; D'alessandria, C; Bonanno, E; Vexler, V; Massari, R; Trotta, C; Scopinaro, F; Dierckx, R et al. (2009). "Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes". Journal of Nuclear Medicine 50 (10): 1683–91. doi:10.2967/jnumed.108.059485. PMID 19759100.
Monoclonal antibodies for the immune system Immune system ("-l(i[m])-") Human ("-limu-")immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab
immune activation: Ipilimumab • Tremelimumab
other: Bertilimumab • ZanolimumabMouse ("-limo-")Chimeric ("-lixi-")Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • VapaliximabHumanized ("-lizu-")immunosuppressive: Aselizumab • Apolizumab • Benralizumab† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412§
non-immunosuppressive: Ibalizumab†Chimeric + humanized
("-lixizu-")Interleukin ("-k(i[n])-") Human ("-kinu-")Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • UstekinumabHumanized ("-kizu-", "-kinzu-")Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • OlokizumabInflammatory lesions ("-les-") Mouse ("-leso-")
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
